Compile Data Set for Download or QSAR
maximum 50k data
Found 7 Enz. Inhib. hit(s) with all data for entry = 1703
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336125(US9738676, Comparative Compound A)
Affinity DataIC50:  0.100nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336122(US9738676, WS2009/106419, Expl. 10)
Affinity DataIC50:  31nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336127(US9738676, Compound of Formula (I-A) according to ...)
Affinity DataIC50:  35nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336126(US9738676, Comparative Compound B)
Affinity DataIC50:  43nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336123(US9738676, WS2009/106419, Expl. 15)
Affinity DataIC50:  71nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM336121(US9738676, WS2009/106419, Expl. 9)
Affinity DataIC50:  300nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica

US Patent
LigandPNGBDBM136699(US8865662, 3 | US9738676, WS2011/018510, Expl. 2)
Affinity DataIC50:  876nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
In DepthDetails US Patent